Literature DB >> 30689086

CGRP in Animal Models of Migraine.

Anne-Sophie Wattiez1,2, Mengya Wang3, Andrew F Russo4,5,6.   

Abstract

With the approval of calcitonin gene-related peptide (CGRP) and CGRP receptor monoclonal antibodies by the Federal Drug Administration, a new era in the treatment of migraine patients is beginning. However, there are still many unknowns in terms of CGRP mechanisms of action that need to be elucidated to allow new advances in migraine therapies. CGRP has been studied both clinically and preclinically since its discovery. Here we review some of the preclinical data regarding CGRP in animal models of migraine.

Entities:  

Keywords:  Animal model; Antibody; CGRP; Migraine

Mesh：

Substances：

Year:  2019        PMID： 30689086      PMCID： PMC7008000          DOI： 10.1007/164_2018_187

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN： 0171-2004


  133 in total

Review 1.  Where do triptans act in the treatment of migraine?

Authors:  Andrew H Ahn; Allan I Basbaum
Journal:  Pain       Date:  2005-05       Impact factor: 6.961

Review 2.  Calcitonin gene-related peptide in the brain, spinal cord, and some peripheral systems.

Authors:  T Hökfelt; U Arvidsson; S Ceccatelli; R Cortés; S Cullheim; A Dagerlind; H Johnson; C Orazzo; F Piehl; V Pieribone
Journal:  Ann N Y Acad Sci       Date:  1992-06-30       Impact factor: 5.691

3.  Increased blood pressure in alpha-calcitonin gene-related peptide/calcitonin gene knockout mice.

Authors:  P R Gangula; H Zhao; S C Supowit; S J Wimalawansa; D J Dipette; K N Westlund; R F Gagel; C Yallampalli
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

4.  Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chronic central pain.

Authors:  A D Bennett; K M Chastain; C E Hulsebosch
Journal:  Pain       Date:  2000-05       Impact factor: 6.961

5.  Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist.

Authors:  M J Cumberbatch; D J Williamson; G S Mason; R G Hill; R J Hargreaves
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.

Authors:  P J Goadsby; L Edvinsson; R Ekman
Journal:  Ann Neurol       Date:  1990-08       Impact factor: 10.422

7.  Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus.

Authors:  S Koulchitsky; M J M Fischer; K Messlinger
Journal:  Cephalalgia       Date:  2008-11-25       Impact factor: 6.292

8.  Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice.

Authors:  Kazutake Tsujikawa; Katsutoshi Yayama; Tamon Hayashi; Hiroaki Matsushita; Taijiro Yamaguchi; Tomomi Shigeno; Yusuke Ogitani; Megumi Hirayama; Tetsuya Kato; So-ichiro Fukada; Shingo Takatori; Hiromu Kawasaki; Hiroshi Okamoto; Masahito Ikawa; Masaru Okabe; Hiroshi Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-08       Impact factor: 11.205

Review 9.  Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis.

Authors:  Robin M van Dongen; Ronald Zielman; Marek Noga; Olaf M Dekkers; Thomas Hankemeier; Arn Mjm van den Maagdenberg; Gisela M Terwindt; Michel D Ferrari
Journal:  Cephalalgia       Date:  2016-09-30       Impact factor: 6.292

10.  Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT(1B/D) agonist.

Authors:  Eric A Kaiser; Adisa Kuburas; Ana Recober; Andrew F Russo
Journal:  J Neurosci       Date:  2012-10-31       Impact factor: 6.167
View more
  7 in total

Review 1.  The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine.

Authors:  Simona Guerzoni; Carlo Baraldi; Luca Pani
Journal:  Neurol Sci       Date:  2022-06-10       Impact factor: 3.830

Review 2.  Innovations and advances in modelling and measuring pain in animals.

Authors:  Katelyn E Sadler; Jeffrey S Mogil; Cheryl L Stucky
Journal:  Nat Rev Neurosci       Date:  2021-11-26       Impact factor: 38.755

3.  The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow.

Authors:  Mária Dux; Birgit Vogler; Annette Kuhn; Kimberly D Mackenzie; Jennifer Stratton; Karl Messlinger
Journal:  Cells       Date:  2022-05-28       Impact factor: 7.666

Review 4.  Dawn of a New RAMPage.

Authors:  D Stephen Serafin; Natalie R Harris; Natalie R Nielsen; Duncan I Mackie; Kathleen M Caron
Journal:  Trends Pharmacol Sci       Date:  2020-02-27       Impact factor: 14.819

5.  Translational Block in Stroke: A Constructive and "Out-of-the-Box" Reappraisal.

Authors:  Athanasios Lourbopoulos; Iordanis Mourouzis; Christodoulos Xinaris; Nefeli Zerva; Konstantinos Filippakis; Angelos Pavlopoulos; Constantinos Pantos
Journal:  Front Neurosci       Date:  2021-05-14       Impact factor: 4.677

6.  Vascular actions of peripheral CGRP in migraine-like photophobia in mice.

Authors:  Bianca N Mason; Anne-Sophie Wattiez; Louis K Balcziak; Adisa Kuburas; William J Kutschke; Andrew F Russo
Journal:  Cephalalgia       Date:  2020-08-18       Impact factor: 6.292

7.  Pharmacological characterisation of mouse calcitonin and calcitonin receptor-like receptors reveals differences compared with human receptors.

Authors:  Michael L Garelja; Rebekah L Bower; Margaret A Brimble; Shanan Chand; Paul W R Harris; Muhammad Aqfan Jamaluddin; Jakeb Petersen; Andrew Siow; Christopher S Walker; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2021-10-15       Impact factor: 8.739
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.